Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.
Patel
Roshani R
RR
Dartmouth Hitchcock Medical Center, Dept. of Surgery, Manchester, NH 03104, USA.
Sengupta
Surojeet
S
Kim
Helen R
HR
Klein-Szanto
Andres J
AJ
Pyle
Jennifer R
JR
Zhu
Fang
F
Li
Tianyu
T
Ross
Eric A
EA
Oseni
Salewa
S
Fargnoli
Joseph
J
Jordan
V Craig
VC
D000409:Alanine / Q000031:analogs & derivatives; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011758:Pyrroles / Q000008:administration & dosage; D011897:Random Allocation; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000037:antagonists & inhibitors; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013629:Tamoxifen / Q000008:administration & dosage; D014183:Transplantation, Heterologous; D014227:Triazines / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D011758:Pyrroles; D014227:Triazines; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D013629:Tamoxifen; C509922:brivanib; C496348:FGFR1 protein, human; D051496:Receptor, Fibroblast Growth Factor, Type 1; D040301:Vascular Endothelial Growth Factor Receptor-2; D000409:Alanine